Cell therapy for patients who have intractable muscle disorders may require highly regenerative cells from young, healthy allogeneic donors. Mesenchymal stem cells are currently under clinical investigation because they are known to induce muscle regeneration and believed to be immune privileged, thus making them suitable for allogeneic applications. However, it is unclear whether allogeneic and myogenic-induced mesenchymal stem cells retain their immunomodulatory characteristics. Therefore, our aim was to evaluate the effects of mesenchymal stem cell differentiation on the immune characteristics of cells in vitro. We investigated the immunologic properties of mesenchymal stem cells after myogenic induction. Mesenchymal stem cells were obtained from C57BL/6 mice and the C3H/10T1/2 murine mesenchymal stem cell line. Two different 5-aza-2′-deoxycytidine doses (0.5 and 3 µM) were evaluated for their effects on mesenchymal stem cell skeletal myogenic differentiation potential, immune antigen expression, and mixed lymphocytic reactions. Using a mixed lymphocytic reaction, we determined the optimal splenocyte proliferation inhibition dose. The induction of regulatory T cells was markedly increased by the addition of 3 µM 5-aza-2′-deoxycytidine-treated mesenchymal stem cells. Myogenic-induced mesenchymal stem cells do not elicit alloreactive lymphocyte proliferative responses and are able to modulate immune responses. These findings support the hypothesis that myogenic-induced mesenchymal stem cells may be transplantable across allogeneic barriers.
Introduction
Bone marrow stem cells have been shown to participate in the regeneration of injured muscle. 1, 2 Bone marrow mesenchymal stem cells (MSCs) are conventionally defined as adherent nonhematopoietic cells expressing several common cell surface antigenic markers, such as CD44, CD73, CD90, and CD105, but not the hematopoietic markers CD34 and CD45. 3 After treatment with inducing agents, 4 MSCs can differentiate in vitro into adipocytes, chondrocytes, and osteocytes; and also into neurons, hepatocytes, pancreatic islets, and muscle. 5 In addition, their ability to evade immunosurveillance after cell transplantation and to suppress the immune response has made MSCs a particularly attractive candidate for clinical use. 6, 7 In particular, it was observed that MSCs could suppress lymphocyte proliferation and activation in response to allogeneic activation or chemical stimulation in vitro and in vivo. [8] [9] [10] MSCs are known to suppress alloantigen-induced T-cell functions in vitro and in vivo and seem to be a promising cell source for the treatment of graft versus host disease (GVHD), osteogenesis imperfect, acute myocardial infarction, and Duchenne muscular dystrophy (DMD). [11] [12] [13] [14] [15] Little is known about the specificity of immunosuppression by MSCs, but these cells are not immunogenic and escape recognition by alloreactive T cells and other effector cells. 16 There are several hypotheses on the immunosuppressive mechanism of MSCs. [17] [18] [19] [20] They are known to induce the increase in regulatory T (Treg) cell activity and also inhibit the maturation and motility of effector cells via production of cytokines such as fractalkine. 21, 22 Another theory states that MSCs induce overproduction of T helper (TH)-2-type cytokines such as interleukin (IL)-10, IL-12, and transforming growth factor (TGF)-β. 23, 24 Clinical interest in MSCs in cell therapy applications is based on their anti-inflammatory properties and ability to release cytokines into the surrounding environment, thereby modifying the developmental fate of neighboring cells. Thus, not only can MSCs themselves be induced to differentiate alone, for example, a myogenic pathway, in which they fuse with myotubes and promote the formation of new muscle fibers, 15 but also in skeletal muscle. For example, they can induce the myogenic differentiation of neighboring satellite cells in the interstitial tissue. 25 Nonetheless, the transplantation of cells already induced to differentiate along the pathway of interest would seem to offer a more direct and readily controllable therapeutic approach than conventional strategies that rely on the innate properties of MSCs to target undifferentiated cell populations. 26 The compound 5-aza-2′-deoxycytidine (5-aza-CdR), an analog of cytidine, causes extensive demethylation of 5-methylcytosine, and reduced DNA methyltransferase (DNMT) activity in the cell 27 has been used in several studies to induce differentiation of MSCs into striated muscle cells. [28] [29] [30] In part, it appears that the mechanism by which 5-aza-CdR activates myogenic genes involves MyoD1. 30 Here, we demonstrate that 5-aza-CdRtreated MSCs showed myogenic conversion. However, the effect of differentiation on the expression profile of immune proteins in allogeneic MSCs is largely unknown.
Allogeneic cell therapy that induces muscle regeneration and has immune-privileged status would provide numerous benefits to patients who have intractable muscle degenerative disorders. Toward this goal, this study aimed to evaluate allogeneic and myogenic-induced MSCs that modulate immune responses. We identified the effects of myogenic MSC induction on cellular antigen profile and lymphocyte proliferation and measured the induction of Treg cells.
Materials and methods

Animals and MSC isolation and culture
All animal work was approved by the Animal Care and Use Committee at Wake Forest University (protocol number: A10-082). Male C57BL/6 mice, 4 to 8 weeks old, were obtained from Charles River Laboratories (Wilmington, MA, USA), housed in a temperature-and light-controlled environment (12L:12D) and were provided food and water ad libitum. For bone marrow cell (BMC) isolation, C57BL/6 mice were killed by CO 2 exposure, and their limbs were subsequently removed. Bone marrow was flushed from medullary cavities of both the femurs and tibiae with Roswell Park Memorial Institute (RPMI)-1640 medium (Invitrogen Life Technologies, Carlsbad, CA, USA) using a 25-gauge needle. For bone marrow MSC isolation, BMCs of C57BL/6 mice were plated at a density of 5 × 10 6 /mL/cm 2 and cultured in an MSC medium containing Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) medium with GlutaMax ™ -I (Invitrogen Life Technologies), 10% MSC-qualified fetal bovine serum (FBS; Invitrogen Life Technologies), and 5 µg/mL gentamicin (Invitrogen Life Technologies) at 37 °C in a 5% CO 2 atmosphere. After 48 h, non-adherent cells were removed by washing with 1× phosphate buffered saline (PBS), and fresh medium was then added. The medium was changed weekly. When the culture was near confluence, the monolayer cells were washed twice with 1× PBS, and then they were lifted by incubation for 2-3 min at 37 °C with a 0.25% trypsin solution containing 0.01% ethylenediaminetetraacetic acid (EDTA; Invitrogen Life Technologies). Trypsin was neutralized by the addition of fresh complete medium. The resulting suspension was then expanded by plating it onto a new culture flask. Murine C3H10T1/2 cells (American Type Culture Collection (ATCC) no. CCL-26; Manassas, VA, USA) were cultured in DMEM supplemented with 10% FBS with 5% CO 2 at 37°C.
Myogenic induction
Twice passaged C57BL/6 BM MSCs and murine C3H10T1/2 cells were seeded into 35-mm dishes at 5000 cells/dish. Beginning 24 h after seeding, these cultures were treated for 24 h with complete medium consisting of DMEM containing 10% FBS, 5% horse serum (HS; Hazleton Biologics, Inc., Lenexa, KS, USA), and 100 U/ mL penicillin and 100 µg/mL streptomycin (Invitrogen Life Technologies) containing two different concentrations (0.5 and 3 µM) of 5-aza-CdR (Sigma Chemical Co., St Louis, MO, USA) at 37 °C in a 5% CO 2 atmosphere. After the cultures were washed twice with PBS, the medium was changed to complete medium without added 5-aza-CdR and subsequently changed twice a week for 2 weeks.
Antibodies
All antibodies used for fluorescence-activated cell sorting (FACS) 
Flow cytometry analysis in myogenic-induced MSCs in vitro
Myogenic-induced and undifferentiated MSCs and murine C3H10T1/2 cells were identified through expressions of desmin, MyHC, CD34, CD45, CD90, CD105, major histocompatibility complex (MHC) class I, MHC class II, CD80, and CD86 at day 14 of culture.
Aliquots of cultured MSCs and murine C3H10T1/2 cells were incubated with primary antibodies (anti-desmin,
, and anti-CD86) for 30 min and kept on ice. Fluorescence isothiocyanate (FITC)-conjugated secondary antibodies (anti-mouse IgG, anti-rabbit IgG anti, anti-goat IgG, and anti-rat IgG) were used to detect primary antibodies. Each fluorescence analysis included appropriate FITC-conjugated negative isotype controls.
The cells were fixed with 1% paraformaldehyde solution and then analyzed with a FACSCalibur ™ flow cytometer (BD Biosciences).
Mixed leukocyte reaction
Mitomycin C (Mit C; 10 µg/mL; Sigma)-treated murine C3H10T1/2 cells (1 × 10 3 to 1 × 10 6 cells) were plated in round-bottom 96-well plates (Corning Inc., Corning, NY, USA) in a total volume of 0.2 mL of MSC medium and maintained 3 h before the T-cell proliferation assays. Splenocytes were isolated from C57BL/6 spleens. For preparation of spleen cell suspensions, spleens were removed and minced with a nylon mesh. After the cells were pelleted, the erythrocytes were lysed using hypotonic buffer containing 0.75% NH 4 Cl. Cells were washed two times in 1× PBS. Spleen cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR, USA) according to the manufacturer's protocol. Briefly, a spleen cell pellet was suspended in pre-warmed serum-free RPMI-1640 media containing 5 µM of CFSE for a final cell concentration of 10 × 10 7 cells/mL. The samples were incubated at 37 °C for 10 min, then centrifuged and washed with pre-warmed complete assay medium (RPMI-1640 supplemented with 10% fetal calf serum (FCS), 10 U/mL penicillin-streptomycin, 2 mM l-glutamine, 10 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 50 µM 2-mercaptoethanol, 1 mM nonessential amino acids (NEAA), and 1 mM sodium pyruvate), and then incubated at 37°C for 10 min to ensure complete probe modification. T-cell proliferation assays were performed in a total 0.2 mL of complete assay medium. To assess proliferation, the CFSE-labeled responding spleen cells (1 × 10 6 ) were cultured alone with phytohemagglutinin (PHA; 10 µg/mL; Sigma) as positive control or was cultured alone with Mit C as negative control or cocultured with Mit C-treated allogeneic MSCs either myogenic induced (5-aza-CdR-treated) or undifferentiated with PHA. Triplicate cultures were incubated at 37°C for 5 days. On day 5 of culture, the cells were harvested for staining with anti-CD3 allophycocyanin (APC) (BD Biosciences). Samples were acquired on a FACSCalibur flow cytometer (BD Biosciences) and data were gated on CD3+ events. The percent of T lymphocytes undergoing division has been identified as the precursor frequency (Pf) indicating how many cells divided at least once. CFSE analyses were determined using FlowJo software (Tree Star Inc., Ashland, OR, USA).
Coculture of splenocyte with C3H10T1/2 cells
Splenocytes isolated from C57BL/6 mice were filtrated through nylon meshes and red blood cells were removed with NH 4 Cl lysis buffer. For coculturing of splenocyte and C3H10T1/2 cells, the C3H10T1/2 cells (1 × 10 4 to 1 × 10 6 cells) were plated onto the lower chambers of transwell culture plate (Corning Inc.) while the splenocytes (1 × 10 6 ) were introduced into the inserted upper chamber (0.4 µm pore size) with complete assay medium. After 5 days of coculture, the splenocytes in the inserted upper chambers were collected and analyzed for determining CD4+ CD25+Foxp3+Treg cell.
Determination of phenotypes of Treg cells by FACS
Phenotypes of Treg cell population in splenocytes cocultured with C3H10T1/2 cells were determined by FACS analysis using Mouse Regulatory T Cell Staining Kit following the manufacturer's protocol (eBioscience, San Diego, CA, USA). Briefly, cells were probed with anti-CD4-FITC and/or anti-CD25-APC for 30 min at 4°C. Next, following fixation, cells were probed for intracellular Foxp3 using phycoerythrin (PE)-labeled anti-Foxp3 antibody or isotype control antibody for 30 min at room temperature or 4°C overnight. Finally, cells were washed with permeabilization buffer and counted using a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed with FlowJo software (Tree Star).
Statistical analysis
The results are expressed as the mean ± standard error of the mean (SEM). The statistical significance was determined by one-way analysis of variance (ANOVA) followed by a Dunn's multiple comparisons test, using GraphPad Prism 6.02 (GraphPad, San Diego, CA, USA). A p value <0.05 was considered significant.
Results
Evidence for myogenic induction
For characterization of BM MSCs and MSC cell line which were used in our experiment, the myogenic differential ability and immunologic markers of these cells were evaluated. Cells were isolated from mouse BM and murine C3H10T1/2 cell line, which contained heterogeneous populations of hematopoietic cells and then purified via adherence separation culturing. After 14 days, the cells from BM MSC and C3H10T1/2 cells were confirmed to have gone through myogenic induction (positive for desmin and MyHC). Immunophenotypic analysis also showed that the cultured cells manifested the typical MSC surface phenotypes. At day 14, the surface phenotype was defined as being positive for CD90 and CD105 and negative for CD34 and CD45. The murine MSC cell line C3H10T1/2 has already been shown to differentiate down the osteogenic, adipogenic, chondrogenic, and myogenic pathways 30, 31 as well as having the same immunosuppressive properties as bone marrow-derived primary human MSCs. 32 MSCs cultured with 5-aza-CdR (to induce myogenic differentiation) formed myotube-like structures after 2 weeks (Figure 1 Figure  1(b) ). MyHC was expressed by 7.41% of 3 µM 5-azaCdR-treated MSCs, 2.79% of 0.5 µM 5-aza-CdR-treated MSCs, and 1.14% of untreated MSCs. The expression of MyHC was more in 3 µM 5-aza-CdR-treated MSCs than in C2C12 (3.63%) (Figure 1(d) ).
MSC markers and immune antigen expression
We carried out flow cytometry to directly compare the expression of MSC markers and immune-related surface markers between untreated MSCs and 5-aza-CdR-treated MSCs. Before experimental use, mouse BM MSCs and C3H10T1/2 were identified by the expression of CD 90 and CD105 antigens but not CD45 or CD34 antigens on day 0 (Supplementary Figure S1) . We also confirmed that the cells we used in the experiment are able to differentiate into lipoblasts. [33] [34] [35] [36] Both 0.5 µM 5-aza-CdR-treated MSCs and 3 µM 5-aza-CdR-treated MSCs were negative for the hematopoietic progenitor/lineage markers CD34 and CD45 after 14 days myogenic induction. The expression of MSC antigens CD90 and CD105 decreased in 5-azaCdR-treated MSCs. Compared with undifferentiated MSCs (33.62%), 3 µM 5-aza-CdR-treated MSCs exhibited half level of CD90 expression (17.09%). By contrast, 0.5 µM 5-aza-CdR-treated MSCs almost lost MSC phenotype (Figure 2(a) ).
Compared with undifferentiated MSCs, 5-aza-CdRtreated MSCs exhibited similar expression of MHC class I and negative expression of MHC class II. T-cell co-stimulatory marker CD80 has no difference between undifferentiated and 5-aza-CdR-treated MSCs. Undifferentiated MSCs were weakly positive for the co-stimulatory molecule CD86, but 5-aza-CdR-treated MSCs showed decreased expression of CD86 (Figure 2(b) ).
Proliferative activity of CD3+ spleen cells cocultured with undifferentiated and 5-azaCdR-treated myogenic-induced MSCs
The ability of MSCs to inhibit activation of lymphocytes by allogeneic spleen cells from C57BL/6 mice and PHA was examined in a CFSE cell proliferation assay. Undifferentiated and 5-aza-CdR-treated MSCs were tested in this assay. Mit C-treated lymphocytes did not proliferate at all (negative control, Figure 3(a) ). Stimulation with PHA induced obvious proliferation of lymphocytes (positive control, Figure 3(a) ). Both undifferentiated and 3 µM 5-aza-CdR-treated MSCs induced exerted dose-dependent inhibition of lymphocyte activation (Figure 3(a) ). MSCs, either undifferentiated or 3 µM 5-aza-CdR-treated MSCs, completely inhibited the proliferation of PHA-stimulated lymphocytes independently for a ratio MSCs:splenocytes equal to 1:1. By contrast, 0.5 µM 5-aza-CdR-treated MSCs did not inhibit lymphocyte activation until the 1:1 ratio.
Pf is a quantitative parameter representing the proliferative responsiveness of the T lymphocytes. Proliferative responsiveness of T lymphocytes in the presence of PHA were significantly greater than undifferentiated (cells in the presence of 0 µM 5-aza-CdR) MSCs (0 µM 5-azaCdR: 8.97 ± 2.1%; PHA: 30.83 ± 5.3%; n = 6; p < 0.05; Figure 3 (b)), whereas there was no significant difference between undifferentiated cells and those treated with 5-aza-CdR (0 µM 5-aza-CdR: 8.97 ± 2.1%; 0.5 µM 5-azaCdR: 15.1 ± 6.8%; 3 µM 5-aza-CdR: 8.2 ± 2.4%; n = 6; not significant (ns); Figure 3(b) ).
Induction of the Treg cells in response to various concentrations of undifferentiated and 5-aza-CdR-treated myogenic-induced MSCs
In order to assess the immunoregulatory function of MSCs related to Treg cells, we designed a transwell assay using the splenocytes from C57BL/6 mice in the presence of various concentrations of undifferentiated and 5-aza-CdR-treated myogenic-induced MSCs. Treg cells were increased with an increase in MSC dose from 10 4 to 10 6 . Addition of undifferentiated MSCs and 5-aza-CdR-treated myogenic-induced MSCs dose dependently increased the proportion of CD4+ Foxp3+ (Figure 4(a) ), CD4+CD25+ (Figure 4(b) ), and CD25+ Foxp3+ (Figure 4(c) ) expression in splenocyte culture by flow cytometry. In the presence of 3 µM 5-aza-CdR-treated MSCs, the proportion of CD4+Foxp3+, CD4+CD25+, and CD25+Foxp3+ expression in splenocytes showed highest. 
Discussion
MSCs contribute to tissue repair and have been used for the regeneration of skeletal muscle and myocardium. 37, 38 MSCs are of interest because of their ability to differentiate to form myogenic cells in situ 26 and may also be immune privileged (suitable for allogeneic applications). We assessed allogeneic and myogenic-induced MSCs for immunomodulatory properties, compared to undifferentiated MSCs.
Two different 5-aza-CdR doses (0.5 39 and 3 µM 40 ) were evaluated for their effects on MSC myogenic differentiation potential, immune antigen expression, and mixed lymphocytic reactions. The 5-aza-CdR-treated MSCs acquired characteristics of myogenic cells and exhibited upregulated expression of late myogenic markers desmin and MyHC. MSCs cultured with 5-aza-CdR also formed myotube-like structures after 2 weeks. Compared with C2C12, 3 µM 5-aza-CdR-treated MSCs exhibited almost half expression of desmin. The expression of MyHC was more in 3 µM 5-aza-CdR-treated MSCs than in C2C12. In this study, 3 µM 5-aza-CdR-treated MSCs showed best result of myogenic induction.
We performed flow cytometry to directly compare the expression of MSC markers and immune-related surface markers between untreated MSCs and 5-aza-CdR-treated MSCs. Both 0.5 µM 5-aza-CdR-treated MSCs and 3 µM 5-aza-CdR-treated MSCs were negative for CD34 and CD45 after 14 days myogenic induction. The expression of MSC antigens CD90 and CD105 decreased in 5-azaCdR-treated MSCs. Compared with undifferentiated MSCs, 3 µM 5-aza-CdR-treated MSCs exhibited half level of CD90 expression. By contrast, 0.5 µM 5-aza-CdRtreated MSCs almost lost MSC phenotype.
MSCs treated with 5-aza-CdR exhibited little expression of MHC class I and negative expression of MHC class II or T-cell co-stimulatory marker CD80, when compared with undifferentiated MSCs. While undifferentiated MSCs were weakly positive for the co-stimulatory molecule CD86, the 5-aza-CdR-treated MSCs showed decreased expression of CD86. This indicates that 5-aza-CdR-treated myogenic-induced MSCs, like undifferentiated MSCs, may not strongly activate rejection responses in allogeneic hosts. Once MSCs differentiate into skeletal muscle, they may lose their immunosuppressive properties. Nonetheless, the differentiated cells might be invisible to the host's immune system because of their low-level expression of MHC class I. This would allow the long-term engraftment of MSCs without rejection following immunosuppressantfree transplantation. 26 We further observed that 3 µM 5-aza-CdR-treated myogenic-induced MSCs, again like undifferentiated MSCs, inhibit PHA-induced activation of lymphocytes in a dose-dependent manner. Using a mixed lymphocytic reaction, we determined the optimal splenocyte proliferation inhibition dose. We titrated the proportion of MSCs relative to that of splenocytes. Under the 1:1 ratio of MSCs:splenocytes, splenocytes' proliferation was inhibited with increase in MSC dose. By contrast, 0.5 µM 5-aza-CdR-treated MSCs did not inhibit lymphocyte activation until the 1:1 ratio and exhibited much stronger proliferation of lymphocytes compared to that of 3 µM 5-aza-CdR-treated MSCs. A major challenge in using MSCs for efficient tissue engineering or therapeutic cell transplantation is to direct their differentiation toward the desired lineage and to have the cells retain this phenotype. 41 It should be noted that 5-aza-CdR is a demethylating agent, and as such, it could induce phenotypic changes that trigger the immune system even without cell differentiation. 26 In this study, 0.5 µM 5-aza-CdR-treated MSCs showed lymphocyte activation and weak myogenic induction. This would be based on the loss of MSCs' phenotype.
How MSCs modulate T-cell activation and hence the ultimate fate of the immune response is a critical unsolved question. But we hypothesized that MSCs induced activation and proliferation of Treg cells. 42 Flow cytometry revealed that addition of undifferentiated MSCs and 5-azaCdR-treated myogenic-induced MSCs dose dependently increased the proportion of CD4+CD25+Foxp3+ expression in splenocyte culture. The role of either soluble factors or cell contact-dependent mechanism in suppression of T-cell response and induction of Treg cells by MSCs is still an unsolved issue. We found that Treg cells increased in the presence of high concentration of MSCs in the present transwell study. Indeed, evidence is available that MSC-derived soluble factors played a role at high MSCs:responders ratio (1:1), 32 whereas at lower ratios, cell contact was required to inhibit immune cell response. 43 In addition, cell contact seems to play a non-redundant role in the induction of CD4+CD25+Foxp3+Treg cell. 44 After culture of CD4+ T cells with MSCs, messenger RNA (mRNA) levels of CD25 and Foxp3 were only increased when cells were in close proximity.
In fact, myogenic induction, particularly 3 µM 5-azaCdR-treated MSCs, enhances the expression of Treg cells. Numerous studies have demonstrated the ability of MSC to induce Treg cells. 42, [45] [46] [47] 52 and augment IL-10 production, 18 which directly inhibits inflammatory signaling. When DC activation is inhibited, MSCs hinder subsequent adaptive immunity by producing Treg cells and attenuating cytotoxic activities of CD8 cells. 45 The compound 5-aza-CdR belongs to a class of cytosine analogs, which is developed as an inhibitor of DNA methylation and has been shown to have significant cytotoxic and antineoplastic activities in many experimental tumors. 53, 54 However, 5-Aza-CdR is reported to be noncarcinogenic and incorporates into DNA but not RNA or protein. 55 Additionally, 5-aza-CdR is approved by the Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS) and is incorporated into the DNA of dividing cells where it specifically inhibits DNA methylation by forming covalent complexes with the DNMTs. 56 Recently, several clinical trials of 5-aza-CdR have been reported, including a phase II study of 5-azaCdR in patients with metastatic prostate cancer and a phase III study of 5-aza-CdR (decitabine) in patients with myelodysplasia. 57 The treatment regimen used in our studies involved 24-h short-term application of 5-aza-CdR 2 weeks before the effects were analyzed. This treatment regime also has the advantage that any toxic effect of 5-aza-CdR would be confined to the 24-h in vitro treatment period since 5-aza-CdR would no longer be present at the end of culture. One could, therefore, envisage implantation of myogenic-induced MSCs into muscle defects or muscle degenerative disorders, without much toxicity concerns.
One limitation of this study is that although we maintained both untreated MSCs and 5-aza-CdR-treated MSCs in culture for 2 weeks, the prolonged cell culture conditions might have introduced factors that confounded the interpretation of MSCs' antigen expression before and after myogenic differentiation. In addition, because we used unpurified spleen cells for the lymphocyte coculture experiments, we do not know whether 5-aza-CdR-treated myogenic-induced MSCs acted as antigen-presenting cells themselves or T cells activated via professional antigenpresenting cells.
In conclusion, the work described herein offers a method to induce allogeneic-and myogenic-differentiated MSCs that are not immunogenic. Myogenic-induced MSCs express little MHC class I, but not MHC class II. Furthermore, myogenic-induced MSCs have an immunomodulatory effect that do not elicit alloreactive lymphocyte proliferative responses and increased the induction of Treg cells. These findings support the view that myogenic-induced MSCs may be transplantable across allogeneic barriers as an immunomodulatory cell therapy source.
